Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug teclistamab tested for safety in Tough-to-Treat blood cancer

NCT ID NCT07030517

Disease control Sponsor: Johnson & Johnson Private Limited Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 28, 2026 · Updated 5 times

Summary

This study tests the safety of teclistamab, a drug given as a shot, in 75 Indian adults with multiple myeloma that has come back or not responded to at least three prior treatments. The goal is to see how safe it is in routine practice. Participants must have tried specific prior therapies and have worsening disease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Teclistamab (a drug given as a shot under the skin)
What this could lead to
If successful, this could confirm that teclistamab is a safe option for Indian patients with hard-to-treat multiple myeloma, potentially offering a new treatment choice.
What could go wrong
This is a small, early-stage safety study (75 participants) in a specific population, so results may not apply broadly. Side effects are possible, and the drug may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

75 people

The number who actually took part.

Started

May 2025

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participant with diagnosed RRMM (as per IMWG definitions or investigator's discretion) who have received at least 3 prior lines of therapy including a proteasome inhibitor, an anti-CD 38 antibody and an immunomodulatory agent and have demonstrated disease progression on the last therapy * Documented evidence of progressive disease on last line of therapy based on investigator's determination of response by IMWG response criteria * Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 * Contraceptive use by female participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. A female participant is eligible to participate if she is not pregnant or breastfeeding, and not a woman of child bearing potential (WOCBP) or is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of less than \[\<\] 1 percent \[%\] per year), preferably with low user dependency, during the treatment period and for a period of 6 months after the last dose of study treatment and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction during study period * A WOCBP must have a negative highly sensitive serum pregnancy test within 24 hours before the first dose of study treatment Exclusion Criteria: * Participants who are not eligible to receive teclistamab as per the locally approved prescribing information * Received any prior B cell maturation antigen (BCMA)-directed therapy * Central nervous system (CNS) involvement or clinical signs of meningeal involvement of multiple myeloma. If either is suspected, negative whole brain MRI, and lumbar cytology are required * Stroke, transient ischemic attack, or seizure within 6 months prior to screening * Participant had major surgery or had significant traumatic injury within 2 weeks prior to enrollment, or will not have fully recovered from surgery, or has major surgery planned during the time the participant is expected to be treated in the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple myeloma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

plasma cell myeloma refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple myeloma

Contacts and locations

Locations

  • All India Institute of Medical Sciences

    New Delhi, 110029, India

  • Bhagwan Mahaveer Cancer Hospital & Research Centre

    Jaipur, 302017, India

  • Christian Medical College

    Ratnagiri Kilminnal, 632517, India

  • Jawaharlal Institute of Postgraduate Medical Education and Research

    Puducherry, 605006, India

  • KIMS-Kingsway Hospitals

    Nagpur, 440001, India

  • M S Ramaiah Medical College and Hospital

    Bangalore, 560054, India

  • Post Graduate Institute of Medical Education And Research PGIMER

    Chandigarh, 160012, India

  • Rajiv Gandhi Cancer Institute & Research Centre

    New Delhi, 110085, India

  • Regional Cancer Centre

    Thiruvananthapuram, 695011, India

  • St. Johns Medical College And Hospital

    Bengaluru, 560034, India

  • Tata Medical Center

    Kolkata, 700156, India

  • Tata Memorial Hospital

    Mumbai, 400012, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.